Lipopolysaccharide activates the muscularis macrophage network and suppresses circular smooth muscle activity

M K Eskandari1, J C Kalff, T R Billiar

  • 1Department of Surgery, University of Pittsburgh Medical School, Pennsylvania 15261, USA.

Insights

Bacterial lipopolysaccharide (LPS) causes sepsis-induced ileus by activating macrophages and leading to inflammation. This study reveals LPS impairs intestinal muscle function and increases leukocyte infiltration in rats.

Area of Science:

  • Gastroenterology
  • Immunology
  • Cellular Biology

Background:

  • Bacterial lipopolysaccharide (LPS) triggers inflammation and is linked to sepsis-induced ileus.
  • The impact of LPS on intestinal muscularis macrophages and inflammation remains under-investigated.

Purpose of the Study:

  • To investigate cellular and functional changes in rat intestinal muscularis following LPS administration.
  • To understand the role of the macrophage network in LPS-induced intestinal dysfunction.

Main Methods:

  • Histology and immunohistochemistry to identify leukocyte populations.
  • Organ bath studies to assess intestinal muscle contractility.
  • Intraperitoneal LPS injection in a rat model.

Main Results:

  • LPS significantly increased lymphocyte activation marker-1 (LFA-1) on macrophages within 1 hour.
  • Neutrophil, mast cell, and monocyte infiltration into the muscularis was observed.
  • A 62% reduction in spontaneous and 91% suppression of stimulated circular muscle activity occurred 12 hours post-LPS.

Conclusions:

  • Endotoxemia acutely activates the intestinal muscularis macrophage network.
  • LPS induces leukocyte extravasation into the muscularis.
  • LPS exposure leads to significant impairment of intestinal circular muscle function.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...